INTRODUCTION {#sec1-1}
============

Gastrointestinal (GI) tract is the most common site of extra-nodal non-Hodgkin′s lymphomas (NHLs), accounting for 15% to 20% of all NHL cases.\[[@CIT1]\] Although secondary involvement of pancreas is seen often in cases of GI lymphoma, primary pancreatic lymphoma (PPL) is an extremely rare disease that can mimic pancreatic carcinoma.\[[@CIT1][@CIT2]\] Fewer than 2% of extra-nodal malignant lymphomas and 0.5% of all pancreatic masses constitute PPL.\[[@CIT3][@CIT4]\] Significant, however, is the fact that PPLs are potentially treatable.\[[@CIT5]\]

To date, approximately 150 cases of PPL have been reported in the English-language medical literature.\[[@CIT6]\] There is no published data on PPL in the Indian population except for a single case report.\[[@CIT7]\]

MATERIALS AND METHODS {#sec1-2}
=====================

We present our experience of treating primary pancreatic lymphoma in patients at our hospital. Medical records of patients identified during a retrospective review of prospectively maintained database in the cancer institute of our hospital were retrieved after obtaining informed consent from the concerned patients. A pathologist reviewed slides and blocks to reconfirm the diagnosis. Literature was accessed on the Internet through PubMed search using the string \'primary pancreatic lymphoma.\'

RESULTS {#sec1-3}
=======

Over a period of 4 years, we have diagnosed and treated 3 cases of primary pancreatic lymphoma \[[Table 1](#T0001){ref-type="table"}\]. All the 3 patients presented with vague abdominal pain of duration ranging from 1½ months to 3 months. Other symptoms reported include low-grade fever in 2 patients, weight loss in 1, loss of appetite in 1 and melena in 1 patient. CT scan showed hypodense mass in body of pancreas (head and tail also in 1 case) encasing the vessels, peri-pancreatic lymph node enlargement with no bile or pancreatic duct dilatation \[[Figure 1](#F0001){ref-type="fig"}\] in all cases. These features are not very typical of a pancreatic malignancy. Two patients had diagnosis confirmed histologically by CT-guided core biopsy or FNA procedure. One patient underwent Whipple′s procedure before the diagnosis was made.

![CT scan showing diffuse homogenous enlargement of pancreatic parenchyma (large arrow) with regional nodal disease (small arrow)](IJMPO-30-20-g001){#F0001}

Hematoxylin and eosin-stained sections from tumor in all the 3 patients showed monotonous population of small round cells in sheets separated by sparse fibrous septae infiltrating the pancreatic parenchyma \[[Figure 2](#F0002){ref-type="fig"}\]. Neoplastic cells had scanty cytoplasm, coarse nuclear chromatin and prominent nucleoli. On immunohistochemistry, all the tumors were positive for CD 20 and negative for CD 3 and were typed as a diffuse large B cell lymphoma of the pancreas.

Two patients received chemotherapy (cyclophosphamide; adriamycin hydrochloride; vincristine and predinosolone --- CHOP regimen) for 4 cycles followed by radiotherapy (45 Gy in 20 fractions for 1 patient and 30 Gy in 18 fractions for the other) using antero-posterior and postero-anterior pair beams. One patient who was diagnosed following Whipple′s procedure received adjuvant chemotherapy with CHOP regimen (6 cycles) alone.

![Photomicrograph of (a) H and E, ×40 section and (b) immunohistochemistry, ×100 of CD 20 from tumor showing monotonous population of small round cells with scanty cytoplasm, coarse nuclear chromatin and prominent nucleoli in the pancreatic parenchyma](IJMPO-30-20-g002){#F0002}

All the patients are currently on follow-up (range, 1-36 months) and are so far free of disease recurrence.

DISCUSSION {#sec1-4}
==========

Diagnostic criteria for PPL include presence of main mass in the pancreas with lymph nodal involvement confined to the peri-pancreatic region with no hepatic or splenic involvement; absence of superficial lymphadenopathy and mediastinal lymph node enlargement; and a normal leukocyte count in peripheral blood.\[[@CIT8][@CIT9]\]

Literature suggests a strong male predominance (male-to-female ratio, 7:1).\[[@CIT6][@CIT10]\]There is no significant difference noted with regard to patient′s age or duration of symptoms between pancreatic adenocarcinoma and PPL.\[[@CIT11]-[@CIT13]\]

Most common presenting symptom reported in literature is abdominal pain, found in about 83% of cases, followed by (in order of frequency) abdominal mass (58%), weight loss (50%), jaundice (37%), acute pancreatitis (12%), small-bowel obstruction (12%) and diarrhea (12%).\[[@CIT1][@CIT3][@CIT6][@CIT8][@CIT9]\] Obstructive jaundice seems to be less frequent in PPL than in pancreatic adenocarcinoma.\[[@CIT8][@CIT9]\] In this series, the most common presenting symptom was vague abdominal pain, as reported previously. One of our patients had low-grade fever, while another had melena, both of which have not been described in this setting.

Usual location of the tumor mass is in the head of the pancreas (more than 80%), with size ranging from 2 to 15 cm.\[[@CIT10][@CIT14]\] In our series, body of the pancreas was the site of disease for all the 3 patients, which is a rare occurrence, with 1 patient having involvement of head and tail of the pancreas.

PPL should be suspected if imaging shows a bulky localized tumor in the pancreatic head without significant dilatation of the main pancreatic duct, infrahilar retroperitoneal enlarged lymph nodes and invasive tumor growth not respecting anatomic boundaries with infiltration of surrounding structures. Enhancement after administration of intravenous contrast medium is usually poor yet homogeneous.\[[@CIT15]\] Presence of calcification or necrosis is usually indicative of pathology other than non-Hodgkin′s lymphoma.

An accurate guided core biopsy for confirmation of diagnosis of PPL is considered a safe, rapid and easy procedure with high diagnostic accuracy.\[[@CIT16][@CIT17]\] We were able to avoid unnecessary laparotomy in 2 patients.

All cases of PPL reported to date in western countries are of the B-cell type, but some cases of T-cell pancreatic lymphoma have been described in Japanese series.\[[@CIT1][@CIT3][@CIT5][@CIT8][@CIT10][@CIT12][@CIT13]\] In our series, all the 3 cases were diffuse large B-cell type, akin to those described in western literature.

Tumor burden, beta-2-microglobulin level above 2 mg/L and LDH level higher than normal are poor prognostic markers.\[[@CIT1][@CIT9][@CIT14][@CIT19]\] Anecdotal cases of elevated CA 19-9 levels in PPL have been reported.\[[@CIT18]\]

Chemotherapy, similar to that for non-Hodgkin′s lymphoma, is the present standard treatment for most patients with PPL, with cure rates of up to 30%.\[[@CIT1][@CIT3]--[@CIT6][@CIT10][@CIT16][@CIT19]\]

The role of surgery is limited to rare occasions such as when FNA or core biopsy is nondiagnostic and open biopsy, therefore, is required.\[[@CIT20]\] Total pancreatectomy (Whipple′s procedure) is considered to have no impact on survival in a patient with PPL and, with its associated morbidity, is not generally recommended for PPL.\[[@CIT16]\]

The role of radiation therapy in the management of PPL is not yet defined. Local radiotherapy up to total 40 Gy has been used as consolidation,\[[@CIT21]\] but data is sparse to draw any conclusions.

Larger series of patients are needed to evaluate whether chemotherapy, eventually followed by involved-field radiation therapy, is the treatment of choice for PPL \[[Table 1](#T0001){ref-type="table"}\].\[[@CIT10][@CIT13]\]

###### 

Clinical and laboratory data of the 3 patients of primary pancreatic lymphoma

  Parameter                                              Case I                      Case II                     Case III                        Reference range
  ------------------------------------------------------ --------------------------- --------------------------- ------------------------------- -----------------
  Age                                                    65                          63                          52                              
  Sex                                                    Female                      Female                      Male                            
  Duration of symptoms                                   3 months                    2 months                    1.5 months                      
  LDH                                                    408.1                       240                         173.2                           0-240 IU/L
  Bilirubin (total)                                      2                           4.2                         6                               0.2-1.0 mg/dL
  Alkaline phosphatase                                   98                          121                         128                             39-117 IU/L
  SGOT                                                   42                          58                          71                              5-38 IU/L
  Amylase                                                68                          78                          143.5                           28-100 IU/L
  CA 19-9                                                78.1                        111.8                       62.2                            0-37 IU/L
  Diagnostic modality                                    CT scan and guided biopsy   CT scan and guided biopsy   Surgery (Whipple's procedure)   
  Chemotherapy                                           CHOP regimen                CHOP regimen                Adjuvant CHOP                   
  Radiotherapy                                           45 Gy in 20 fractions       30 Gy in 18 fractions       Planned                         
  Follow-up duration[\*](#T000F1){ref-type="table-fn"}   36 months                   25 months                   1 month                         
  Status at last follow-up                               NED                         NED                         NED                             

CHOP regimen = Cyclophosphamide, doxorubicin hydrochloride, vincristine and predinosolone; NED = No evidence of disease;

= Since completion of chemotherapy
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